

stable prices, and moderate long-term interest rates.”<sup>2</sup> Section 10 of the FRA authorizes the Board to “determine and prescribe the manner in which its obligations shall be incurred and its disbursements and expenses allowed and paid.”<sup>3</sup> Providing information collected as part of the Application is required to obtain a benefit.

Generally, information provided on the Application may be kept confidential from the public under exemption 6 of the Freedom of Information Act (FOIA) to the extent that the disclosure of the information “would constitute a clearly unwarranted invasion of personal privacy.” For example, the release of information such as the applicant’s address, home telephone number, or personal email address to the public would likely constitute a clearly unwarranted invasion of personal privacy and be kept confidential. However, the release of information such as the educational and professional qualifications of successful applicants would not likely constitute a clearly unwarranted invasion of personal privacy and may be disclosed under the FOIA. In addition, once a person becomes a member of the CAC, their name, and the name and location of the organization where they are employed, would generally be listed on the Board’s public website.

**Current actions:** On October 5, 2021, the Board published a notice in the **Federal Register** (86 FR 54977) requesting public comment for 60 days on the extension, without revision, of the Application Form for Membership on the Community Advisory Committee Council. The comment period for this notice expired on December 6, 2021. The Board did not receive any comments.

Board of Governors of the Federal Reserve System, February 14, 2022.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2022–03471 Filed 2–16–22; 8:45 am]

**BILLING CODE 6210–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Proposed Information Collection Activity; FFY 2022 CCDF Discretionary Funds Reallotment (0970–0510)

**AGENCY:** Office of Child Care, Administration for Children and Families, HHS.

**ACTION:** Request for public comment.

**SUMMARY:** The Administration for Children and Families (ACF), Office of Child Care (OCC) plans to submit a generic information collection (GenIC) request under the following umbrella generic: Generic Clearance for Financial Reports used for ACF Mandatory Grant Programs (0970–0510). This request includes a draft announcement with instructions to be completed by Child Care and Development Fund (CCDF) grant recipients that will be unable to obligate funds that will reach the end of their obligation period on September 30, 2022.

**DATES:** *Comments due within 14 days of publication.* In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above and below.

**ADDRESSES:** Copies of the proposed collection of information can be obtained and comments may be submitted by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). All requests should be identified by the title of the information collection.

#### SUPPLEMENTARY INFORMATION:

**Description:** CCDF regulations authorize HHS to reallot funds to other state and tribal lead agencies that cannot be obligated by states or tribes by the obligation deadline. Pursuant to the CCDF Rule (45 CFR 98.64), each year, the state and tribal lead agency must report to the Secretary the dollar amount from the previous year’s grant that it will be unable to obligate by the end of the obligation period. Such

reports must be postmarked or emailed by April 1. If the Secretary does not receive a report, any funds that are not obligated by the obligation deadline will revert to the Federal Government.

For the purposes of this data collection, “state” refers to the 50 states, the District of Columbia, and the Commonwealth of Puerto Rico.

The Generic Clearance for Financial Reports used for ACF Mandatory Grant Programs allows ACF programs to assist in the computation of the grant awards issued to each program’s grantees. For more information about the umbrella generic, see: [https://www.reginfo.gov/public/do/PRAViewDocument?ref\\_nbr=202108-0970-002](https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=202108-0970-002).

This specific GenIC will be issued as a Program Instruction and an email announcement on the OCC listserv. State and tribal lead agencies that will be unable to obligate their funds by September 30, 2022, must inform ACF by April 1, 2022. Lead Agencies should submit a letter by mail or email signed by an official authorized to make financial decisions (e.g., Tribal Chair, Agency Director) to their OCC Regional Program Manager and ACF Regional Grants Management Specialist. The letter or email should report the amount of funds for each of the following funding streams that the Lead Agency will be unable to obligate: Grant year 2021 CCDF discretionary funds, and CCDF supplemental funds awarded under the Additional Supplemental Appropriations for Disaster Relief Act, 2019 (Pub. L. 116–20); the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116–136); the Coronavirus Response and Relief Supplemental Appropriations Act (Pub. L. 116–260); and the American Rescue Plan Act child care stabilization funds (Pub. L. 117–2). ACF will de-obligate funds that are reported and re-allot those funds to state and tribal lead agencies that request the funds.

**Respondents:** Respondents will be state and tribal officials authorized to report on behalf of the CCDF program, which will likely be CCDF program administrators.

#### ANNUAL BURDEN ESTIMATES

| Title of information collection                         | Number of respondents | Annual frequency of responses | Hourly burden per response | Annual hourly burden |
|---------------------------------------------------------|-----------------------|-------------------------------|----------------------------|----------------------|
| FFY 2022 CCDF Discretionary Funds for Reallotment ..... | 317                   | 1                             | 1                          | 317                  |

<sup>2</sup> 12 U.S.C. 225a.

<sup>3</sup> 12 U.S.C. 244. This authority permits the Board to collect personal information (e.g., bank account

routing numbers) needed to disburse travel funds to CAC members.

*Estimated Total Annual Burden Hours: 317.*

*Comments:* The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 14 days of this publication.

*Authority:* 45 CFR 98.64.

**Mary B. Jones,**

*ACF/OPRE Certifying Officer.*

[FR Doc. 2022-03462 Filed 2-16-22; 8:45 am]

**BILLING CODE 4184-55-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2019-N-0895]

#### Issuance of Priority Review Voucher; Material Threat Medical Countermeasure Product

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a material threat medical countermeasure (MCM) product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the 21st Century Cures Act (Cures Act), authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that **SPIKEVAX** (COVID-19 Vaccine, mRNA), meets the criteria for a material threat priority review voucher, which has been issued to ModernaTX, Inc., the holder of the biologics license application.

**FOR FURTHER INFORMATION CONTACT:** Myrna Hanna, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301,

Silver Spring, MD 20993-0002, 240-402-7911.

**SUPPLEMENTARY INFORMATION:** FDA is announcing the issuance of a material threat MCM priority review voucher to the sponsor of an approved material threat MCM product application. Under section 565A of the FD&C Act (21 U.S.C. 360bbb-4a), which was added by the Cures Act (Pub. L. 114-255), FDA will award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria upon approval of those applications. FDA has determined that **SPIKEVAX** (COVID-19 Vaccine, mRNA), meets the criteria for a material threat MCM priority review voucher. **SPIKEVAX** is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

For further information about the material threat MCM Priority Review Voucher Program and for a link to the full text of section 565A of the FD&C Act, go to <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/mcm-related-counterterrorism-legislation>. For further information about **SPIKEVAX**, (COVID-19 Vaccine, mRNA), go to the Center for Biologics Evaluation and Research Approved Vaccine Products website at <https://www.fda.gov/vaccines-blood-biologics/vaccines/approved-vaccine-products>.

Dated: February 11, 2022.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2022-03420 Filed 2-16-22; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2021-N-0386]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Class II Special Controls for Human Immunodeficiency Virus Serological Diagnostic and Supplemental Tests and Human Immunodeficiency Virus Nucleic Acid Diagnostic and Supplemental Tests

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Submit written comments (including recommendations) on the collection of information by March 21, 2022.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting "Currently under Review—Open for Public Comments" or by using the search function. The OMB control number for this information collection is 0910-0437. Also include the FDA docket number found in brackets in the heading of this document.

#### FOR FURTHER INFORMATION CONTACT:

Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, [PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

#### Medical Device Reporting—21 CFR Part 803

*OMB Control Number 0910-0437—Revision*

In the **Federal Register** of February 21, 2020 (85 FR 10110), we published a proposed order to reclassify certain human immunodeficiency virus (HIV) serological diagnostic and supplemental tests and HIV nucleic acid (NAT) diagnostic and supplemental tests from class III (premarket approval) into class II (special controls) (the proposed order). In the proposed order, FDA proposed special controls that the Agency believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices. The proposed special controls would require the submission of a log of all complaints annually for a period of 5 years following FDA clearance of a traditional premarket notification (510(k)) submission for a device within the scope of the proposed order.

Currently, manufacturers of HIV serological diagnostic and supplemental tests and HIV NAT diagnostic and supplemental tests are subject to FDA